Human bone marrow niche chemoprotection mediated by cytochrome p450 enzymes

Oncotarget

Volumn 6, Issue 17, 2015, Pages 14905-14912

  Alonso, Salvador ^a   Su, Meng ^a   Jones, Jace W ^b   Ganguly, Sudipto ^a   Kane, Maureen A ^b   Jones, Richard J ^a   Ghiaur, Gabriel ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

CYP; Drug resistance; Leukemia; Microenvironment; Multiple myeloma

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOCHROME P450; CYTOCHROME P450 3A; DEXAMETHASONE; IL2RG PROTEIN, MOUSE; INTERLEUKIN 2 RECEPTOR GAMMA; LENALIDOMIDE; RETINOIC ACID; THALIDOMIDE;

ANALOGS AND DERIVATIVES; ANIMAL; BONE MARROW; DEFICIENCY; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KNOCKOUT MOUSE; MESENCHYMAL STROMA CELL; METABOLISM; NEOPLASMS; NONOBESE DIABETIC MOUSE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SCID MOUSE; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW; CELL LINE, TUMOR; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; MESENCHYMAL STROMAL CELLS; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; THALIDOMIDE; TRETINOIN; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84934343397     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3614     Document Type: Article

References (37)

1. Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia. 2003; 17:1175-1182.
2. Hao M, Zhang L, An G, Meng H, Han Y, Xie Z, Xu Y, Li C, Yu Z, Chang H, Qiu L. Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression. Leukemia & lymphoma. 2011; 52:1787-1794.
3. Garrido SM, Appelbaum FR, Willman CL, Banker DE. Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Experimental hematology. 2001; 29:448-457.
4. Estey E, Dohner H. Acute myeloid leukaemia. Lancet. 2006; 368:1894-1907.
5. Krause DS, Scadden DT, Preffer FI. The hematopoietic stem cell niche-home for friend and foe? Cytometry Part B, Clinical cytometry. 2013; 84:7-20.
6. Meads MB, Gatenby RA, Dalton WS. Environmentmediated drug resistance: a major contributor to minimal residual disease. Nature reviews Cancer. 2009; 9:665-674.
7. Gojo I, Karp JE. New strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine. Clinical cancer research: an official journal of the American Association for Cancer Research. 2014; 20:6233-6241.
8. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 1994; 77:491-502.
9. Ghosn J, Chaix ML, Peytavin G, Rey E, Bresson JL, Goujard C, Katlama C, Viard JP, Treluyer JM, Rouzioux C. Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. Aids. 2004; 18:1958-1961.
10. Ghiaur G, Yegnasubramanian S, Perkins B, Gucwa JL, Gerber JM, Jones RJ. Regulation of human hematopoietic stem cell self-renewal by the microenvironment's control of retinoic acid signaling. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110:16121-16126.
11. Ahdjoudj S, Lasmoles F, Oyajobi BO, Lomri A, Delannoy P, Marie PJ. Reciprocal control of osteoblast/chondroblast and osteoblast/adipocyte differentiation of multipotential clonal human marrow stromal F/STRO-1(+) cells. Journal of cellular biochemistry. 2001; 81:23-38.
12. Campeau E, Ruhl VE, Rodier F, Smith CL, Rahmberg BL, Fuss JO, Campisi J, Yaswen P, Cooper PK, Kaufman PD. A versatile viral system for expression and depletion of proteins in mammalian cells. PloS one. 2009; 4:e6529.
13. Guengerich FP. Cytochrome p450 and chemical toxicology. Chemical research in toxicology. 2008; 21:70-83.
14. Seliskar M, Rozman D. Mammalian cytochromes P450-importance of tissue specificity. Biochimica et biophysica acta. 2007; 1770:458-466.
15. May JE, Xu J, Morse HR, Avent ND, Donaldson C. Toxicity testing: the search for an in vitro alternative to animal testing. British journal of biomedical science. 2009; 66:160-165.
16. Fujita K. Cytochrome P450 and anticancer drugs. Current drug metabolism. 2006; 7:23-37.
17. Niesvizky R, Jayabalan DS, Christos PJ, Furst JR, Naib T, Ely S, Jalbrzikowski J, Pearse RN, Zafar F, Pekle K, Larow A, Lent R, Mark T, Cho HJ, Shore T, Tepler J, et al. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete-and overallresponse rates in treatment-naive symptomatic multiple myeloma. Blood. 2008; 111:1101-1109.
18. Gay F, Rajkumar SV, Coleman M, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard J, Lacy MQ, Chen-Kiang S, Roy V, Jayabalan DS, Lust JA, Witzig TE, Fonseca R, et al. Clarithromycin (Biaxin)-lenalidomidelow-dose dexamethasone (BiRd) versus lenalidomide-lowdose dexamethasone (Rd) for newly diagnosed myeloma. American journal of hematology. 2010; 85:664-669.
19. Ghosh N, Tucker N, Zahurak M, Wozney J, Borrello I, Huff CA. Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma. American journal of hematology. 2014; 89:E116-120.
20. Durie BGM, Villarete L, Farvard A, Ornopia M, Urnovitz HB. Clarithromycin (Biaxin(R)) as primary treatment for myeloma. Blood. 1997; 90:2578-2578.
21. Stewart AK, Trudel S, Al-Berouti BM, Sutton DM, Meharchand J. Lack of response to short-term use of clarithromycin (BIAXIN) in multiple myeloma. Blood. 1999; 93:4441.
22. Moreau P, Huynh A, Facon T, Bouilly I, Sotto JJ, Legros L, Milpied N, Attal M, Bataille R, Harousseau JL. Lack of efficacy of clarithromycin in advanced multiple myeloma. Intergroupe Francais du Myelome (IFM). Leukemia. 1999; 13:490-491.
23. Spicer ST, Liddle C, Chapman JR, Barclay P, Nankivell BJ, Thomas P, O'Connell PJ. The mechanism of cyclosporine toxicity induced by clarithromycin. British journal of clinical pharmacology. 1997; 43:194-196.
24. Niemi M, Neuvonen PJ, Kivisto KT. The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide. Clinical pharmacology and therapeutics. 2001; 70:58-65.
25. Relling MV, Evans R, Dass C, Desiderio DM, Nemec J. Human cytochrome P450 metabolism of teniposide and etoposide. The Journal of pharmacology and experimental therapeutics. 1992; 261:491-496.
26. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nature reviews Cancer. 2013; 13:714-726.
27. Matsunaga T, Takemoto N, Sato T, Takimoto R, Tanaka I, Fujimi A, Akiyama T, Kuroda H, Kawano Y, Kobune M, Kato J, Hirayama Y, Sakamaki S, Kohda K, Miyake K, Niitsu Y. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nature medicine. 2003; 9:1158-1165.
28. Azab AK, Runnels JM, Pitsillides C, Moreau AS, Azab F, Leleu X, Jia X, Wright R, Ospina B, Carlson AL, Alt C, Burwick N, Roccaro AM, Ngo HT, Farag M, Melhem MR, et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood. 2009; 113:4341-4351.
29. Bewry NN, Nair RR, Emmons MF, Boulware D, Pinilla-Ibarz J, Hazlehurst LA. Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Molecular cancer therapeutics. 2008; 7:3169-3175.
30. Zhuo X, Zheng N, Felix CA, Blair IA. Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug metabolism and disposition: the biological fate of chemicals. 2004; 32:993-1000.
31. Wang L, Christopher LJ, Cui D, Li W, Iyer R, Humphreys WG, Zhang D. Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug metabolism and disposition: the biological fate of chemicals. 2008; 36:1828-1839.
32. Uttamsingh V, Lu C, Miwa G, Gan LS. Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug metabolism and disposition: the biological fate of chemicals. 2005; 33:1723-1728.
33. Sandanaraj E, Lal S, Selvarajan V, Ooi LL, Wong ZW, Wong NS, Ang PC, Lee EJ, Chowbay B. PXR pharmacogenetics: association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008; 14:7116-7126.
34. Doherty D, Dvorkin SA, Rodriguez EP, Thompson PD. Vitamin D receptor agonist EB1089 is a potent regulator of prostatic "intracrine" metabolism. The Prostate. 2014; 74:273-285.
35. Chen Y, Tang Y, Chen S, Nie D. Regulation of drug resistance by human pregnane X receptor in breast cancer. Cancer biology & therapy. 2009; 8:1265-1272.
36. Rochat B. Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism. Clinical pharmacokinetics. 2005; 44:349-366.
37. Ohara T, Morishita T, Suzuki H, Masaoka T, Ishii H, Hibi T. Antibiotics directly induce apoptosis in B cell lymphoma cells derived from BALB/c mice. Anticancer research. 2004; 24:3723-3730.